BR112017024821A2 - nanopartículas radioativas e métodos de fabricação e utilização das mesmas - Google Patents

nanopartículas radioativas e métodos de fabricação e utilização das mesmas

Info

Publication number
BR112017024821A2
BR112017024821A2 BR112017024821A BR112017024821A BR112017024821A2 BR 112017024821 A2 BR112017024821 A2 BR 112017024821A2 BR 112017024821 A BR112017024821 A BR 112017024821A BR 112017024821 A BR112017024821 A BR 112017024821A BR 112017024821 A2 BR112017024821 A2 BR 112017024821A2
Authority
BR
Brazil
Prior art keywords
nanoparticle
metal
radioactive
core
metal coating
Prior art date
Application number
BR112017024821A
Other languages
English (en)
Inventor
Moeendarbari Sina
Sun Xiankai
Hao Yaowu
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/719,921 external-priority patent/US9801962B2/en
Application filed by Univ Texas filed Critical Univ Texas
Publication of BR112017024821A2 publication Critical patent/BR112017024821A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/183—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an inorganic material or being composed of an inorganic material entrapping the MRI-active nucleus, e.g. silica core doped with a MRI-active nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Powder Metallurgy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Manufacture Of Metal Powder And Suspensions Thereof (AREA)

Abstract

em um aspecto, nanopartículas radioativas são descritas neste documento. em algumas modalidades, uma nanopartícula radioativa descrita neste documento compreende um núcleo metálico de nanopartícula, um revestimento metálico externo disposto ao longo do núcleo metálico de nanopartícula e um radioisótopo metálico disposto dentro do núcleo metálico de nanopartícula ou dentro do revestimento metálico externo. em alguns casos, a nanopartícula radioativa tem um tamanho em uma faixa de cerca de 30-500 em três dimensões. além disso, em algumas modalidades, a nanopartícula radioativa compreende ainda um revestimento metálico interno disposto entre o núcleo de nanopartículas metálicas e o revestimento metálico externo. o núcleo metálico de nanopartículas, o revestimento metálico externo e o revestimento metálico interno da nanopartícula radioativa podem ter várias composições metálicas.
BR112017024821A 2015-05-22 2016-05-20 nanopartículas radioativas e métodos de fabricação e utilização das mesmas BR112017024821A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/719,921 US9801962B2 (en) 2010-06-16 2015-05-22 Radioactive nanoparticles and methods of making and using the same
PCT/US2016/033432 WO2016191247A1 (en) 2015-05-22 2016-05-20 Radioactive nanoparticles and methods of making and using the same

Publications (1)

Publication Number Publication Date
BR112017024821A2 true BR112017024821A2 (pt) 2018-08-07

Family

ID=57393667

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017024821A BR112017024821A2 (pt) 2015-05-22 2016-05-20 nanopartículas radioativas e métodos de fabricação e utilização das mesmas

Country Status (8)

Country Link
EP (1) EP3297685B1 (pt)
JP (1) JP6810461B2 (pt)
KR (1) KR20180010222A (pt)
CN (1) CN107921153B (pt)
AU (1) AU2016268064B2 (pt)
BR (1) BR112017024821A2 (pt)
CA (1) CA2986620C (pt)
WO (1) WO2016191247A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3041931A1 (en) * 2018-05-02 2019-11-02 Royal Melbourne Institute Of Technology A multimodal pet/mri contrast agent and a process for the synthesis thereof
CN109187484B (zh) * 2018-09-13 2020-12-04 广西师范大学 一种用亲和反应调控碳点催化sers检测生物素的方法
KR102456660B1 (ko) * 2019-07-18 2022-10-18 경희대학교 산학협력단 베타 붕괴를 이용한 인공신경망모사 소자 및 이에 사용되는 나노입자
CN111906328B (zh) * 2020-08-11 2022-10-25 苏州大学 一种177Lu标记的金纳米团簇及其制备方法和应用
US11266740B1 (en) 2020-09-04 2022-03-08 King Abdulaziz University Noble metal nanoparticles with radial pores
CN114381255B (zh) * 2021-10-25 2022-10-11 中国科学院福建物质结构研究所 一种放射性医用同位素标记的稀土掺杂纳米材料和pet显像诊疗剂及其制备方法和应用
US20240042071A1 (en) * 2022-07-13 2024-02-08 Achille Cester Process for making active carriers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9040157B2 (en) * 2010-06-16 2015-05-26 Board Of Regents, The University Of Texas System Hollow nanoparticles and nanocomposites and methods of making hollow nanoparticles and nanocomposites
US9242016B2 (en) * 2011-01-03 2016-01-26 The Curators Of The University Of Missouri Gold coated lanthanide nanoparticles
US8197471B1 (en) * 2011-02-14 2012-06-12 Samuel Harry Tersigni Core-excited nanoparticles and methods of their use in the diagnosis and treatment of disease

Also Published As

Publication number Publication date
WO2016191247A1 (en) 2016-12-01
KR20180010222A (ko) 2018-01-30
AU2016268064A1 (en) 2017-11-23
EP3297685B1 (en) 2021-02-17
JP2018520098A (ja) 2018-07-26
AU2016268064B2 (en) 2021-07-22
JP6810461B2 (ja) 2021-01-06
CA2986620A1 (en) 2016-12-01
CA2986620C (en) 2021-08-03
CN107921153A (zh) 2018-04-17
CN107921153B (zh) 2021-06-11
EP3297685A1 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
BR112017024821A2 (pt) nanopartículas radioativas e métodos de fabricação e utilização das mesmas
PL3630917T3 (pl) Równomiernie zamknięte nanocząstki i ich zastosowania
SG10202105352UA (en) "identifying an entity"
AU201611490S (en) An air freshener housing
AU201611467S (en) Face mask frame
FR3009645B1 (fr) Compositions de nanoparticules d'oxydes metalliques transparents, procedes de fabrication de celles-ci et articles comprenant celles-ci
AU363510S (en) 1) Air conditioner 2) air conditioner cassette
AU363508S (en) 1) Air conditioner 2) air conditioner cassette
IL286795A (en) A deodorizer containing zinc neodecanoate
HUE061418T2 (hu) Glükokortikoszteroid-nanorészecskéket tartalmazó vizes szuszpenziós szer
EP3706801A4 (en) PLATINUM COMPLEXES AND THEIR USES
EP3508594B8 (en) TiAI ALLOY AND METHOD OF MANUFACTURING THE SAME
CL2019003182A1 (es) Resinas compuestas que contienen nanoparticulas de plata.
AU363569S (en) 1) Air conditioner 2) air conditioner cassette
EP3124582A4 (en) Aqueous lubricating coating agent having excellent corrosion resistance and workability, and metal material
EP3433225A4 (en) NOVEL DERIVATIVES OF CURCUMINOIDS AND USE THEREOF AS AN ANTICROPHANT
EP3490611A4 (en) ANTIBODY-CONJUGATED NANOPARTICLES AND MEDICAL USES THEREOF
MA43648A (fr) Conjugués de nanoparticules
CL2015003652A1 (es) Película adhesiva traslucida con actividad antibacteriana, protectora de superficies, que comprende nanoparticulas de cobre, su método de preparación y su uso para proteger superficies de alta exposición a presencia de bacterias y hongos
SG11202004645UA (en) Spherical ti-based powder and manufacturing method therefor
EP3563861C0 (en) GINSENG NANOPARTICLES AND THE PRODUCTION AND USE THEREOF
IT201700067461A1 (it) Nuovi estratti di bergamotto, loro combinazioni e formulazioni che li contengono
ITUA20162869A1 (it) Associazione di glicosamminoglicani e un agente antiacido e composizioni che la contengono.
TH165683A (th) องค์ประกอบสำหรับใช้ในช่องปากที่มีโลหะไอออน
AU201713001S (en) Vehicle gate stop

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]